Kither Biotech Doses First Patients in KIT2014 COPD Trial
TURIN, Italy — September 29, 2026 Kither Biotech Pty Ltd and Kither Biotech Srl announced that the first patients...
metabolic disease
Advertisement
Caspian Unveils KO-7246 Preclinical Diabetes Data at EASD
SAN DIEGO — September 29, 2026 Caspian Therapeutics and Kura Oncology announced new preclinical data for KO-7246, an investigational,...
MediciNova Reports Phase 2 MN-001 Results in Metabolic Disease
LA JOLLA, Calif. — September 28, 2026 MediciNova, Inc. reported topline results from the randomized, double-blind, placebo-controlled MN-001-NATG-202 Phase...
Marea Therapeutics and Lisata to Present MAR001 Phase 2b Data
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J. — September 24, 2026 Marea Therapeutics, a subsidiary of Lisata Therapeutics,...
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Advertisements
Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
Arcturus to Present ARCT-810 Phase 2 OTC Deficiency Data
SAN DIEGO — September 18, 2026 Arcturus Therapeutics announced plans to provide an update on its ARCT-810 Phase 2...
Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
Corbus Advances CRB-913 Toward Phase 2 in Obesity
NORWOOD, Mass. — September 14, 2026 Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b...
Advertisement
